Associated Papers
Phenotypic characterization of a new case of multiple endocrine neoplasia type 4 associated with de novo germline and somatic CDKN1B pathogenic variants.
Benderradji H et al.
Annales D'endocrinologie, 2025
Beyond MEN1, When to Think About MEN4? Retrospective Study on 5600 Patients in the French Population and Literature Review.
Chevalier B et al.
The Journal of Clinical Endocrinology and Metabolism, 2024
Novel germline variants of CDKN1B and CDKN2C identified during screening for familial primary hyperparathyroidism.
Mazarico-Altisent I et al.
Journal of Endocrinological Investigation, 2023
36334246 (PubMed )
Supplement: 40618_2022_1948_MOESM1_ESM.xlsx › Supplementary_material
Multiple endocrine neoplasia type 4: a new member of the MEN family.
Singeisen H et al.
Endocrine Connections, 2023
JAK3 mutations and mitochondrial apoptosis resistance in T-cell acute lymphoblastic leukemia.
Bodaar K et al.
Leukemia, 2022
35411095 (PubMed )
Supplement: NIHMS1792675-supplement-Supplementary_Table_2.xlsx › Sheet_1
Co-occurrence of multiple endocrine neoplasia type 4 and spinal neurofibromatosis: a case report.
Brock P et al.
Familial Cancer, 2020
Fanconi-BRCA pathway mutations in childhood T-cell acute lymphoblastic leukemia.
Pouliot GP et al.
Plos One, 2019
31721781 (PubMed )
Supplement: pone.0221288.s012.xlsx › Sheet_1
Hedgehog pathway mutations drive oncogenic transformation in high-risk T-cell acute lymphoblastic leukemia.
Burns MA et al.
Leukemia, 2018
29654263 (PubMed )
Supplement: NIHMS944706-supplement-Table_S2.xlsx › Table_S2
Select a paper to view details